Catalyst Event
Giant Biogene Holding Co Ltd (2367) · Other
From Akros SCHK HK-Korea Biotech Index (ASHKBIO)
4/30/2026, 12:00:00 AM
On April 30, 2026, the board of directors announced its proposal to appoint KPMG as the new auditor, replacing Ernst & Young, subject to shareholder approval. Importance is Low as auditor changes typically result in a minor market reaction of approximately 1%.
Korean Translation
2026년 4월 30일 이사회가 주주총회 승인을 조건으로 기존 외부감사인인 언스트앤영을 대신하여 KPMG를 신규 외부감사인으로 선임할 것을 제안함. 외부감사인 변경은 통상적으로 주가에 약 1% 내외의 미미한 영향을 미치므로 중요도를 'Low'로 설정함.
Related Recent Events
Samchundang Pharm Co Ltd (000250) · Other
Extraordinary shareholders' meeting to appoint a former Financial Supervisory Service (FSS) official as a new outside director on June 30, 2026. Low importance is estimated as board changes typically have minimal immediate price impact, scheduled.
6/30/2026, 12:00:00 AM
LigaChem Biosciences Inc (141080) · Earnings Release
The company's quarterly earnings report is scheduled for May 18, 2026; a 5-10% price impact is estimated based on historical volatility, scheduled.
5/18/2026, 12:00:00 AM
Samchundang Pharm Co Ltd (000250) · Earnings Release
Q1 2026 earnings release on May 18, 2026. Low importance is estimated as the announcement of the release date itself usually results in minimal price movement, scheduled.
5/18/2026, 12:00:00 AM
Celltrion Inc (068270) · Earnings Release
Celltrion is scheduled to announce its Q1 2026 earnings on May 8, 2026. Analysts forecast consolidated sales of approximately 1.12 trillion KRW and an operating profit of around 314 billion KRW, which is estimated to have a medium market impact (≥5%) scheduled.
5/8/2026, 12:00:00 AM
Samsung Biologics Co Ltd (207940) · Other
The company's labor union has threatened its first-ever general strike to begin on May 1, 2026, following the breakdown of wage negotiations. Analysts forecast a price impact of over 10% due to significant operational risks, expected.
5/1/2026, 12:00:00 AM
Celltrion Inc (068270) · Other
Celltrion applied for marketing authorization to the European Medicines Agency (EMA) for 'Herzuma SC', a subcutaneous formulation of its breast cancer biosimilar Trastuzumab, on April 30, 2026. This first-in-class formulation is estimated to have a high market impact (≥10%) due to its significant competitive advantage.
4/30/2026, 12:00:00 AM